CSF1R-IN-2 manufacturers
- CSF1R-IN-2
-
- $34.00
-
2026-07-27
- CAS:2271119-26-5
- Purity: 99.71%
- Supply Ability: 10g
- CSF1R-IN-2
-
- $34.00
-
2026-07-27
- CAS:2271119-26-5
- Purity: 99.71%
- Supply Ability: 10g
|
| | CSF1R-IN-2 Basic information |
| Product Name: | CSF1R-IN-2 | | Synonyms: | CSF1R-IN-2;CSF1R inhibitor 2;1,15-Etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile, 3-amino-14-ethyl-11-fluoro-4,5,6,7,13,14-hexahydro-7-methyl-4-oxo-, (7S)-;TPX-0022(CSF1R-IN-2);Elzovantinib (TPX-0022);colony stimulating factor 1 receptor,CSF-1R,CSF1R IN 2,inhibit,CSF1RIN2,c-Met/HGFR,CSF1R,CSF-1R-IN-2,Inhibitor,CSF-1 receptor,Src,c-Fms;(S)-12-Amino-2-ethyl-45-fluoro-6-methyl-9-oxo-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphane-46-carbonitrile;CSF1R-IN-2, 10 mM in DMSO | | CAS: | 2271119-26-5 | | MF: | C20H20FN7O2 | | MW: | 409.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2271119-26-5.mol |  |
| | CSF1R-IN-2 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 25 mg/mL (61.06 mM; Need ultrasonic) | | form | A solid | | color | White to off-white |
| | CSF1R-IN-2 Usage And Synthesis |
| Uses | Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively[1]. | | in vivo | Elzovantinib (TPX-0022; p.o., BID, 13 days) treatment results in an 85% tumor regression and no body weight loss is observed after 21 days treatment in mice[1].
Elzovantinib (p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively in SCID/Beige mice[1].
Elzovantinib inhibits MET activity in MKN-45 tumors following oral administration in mice[1].
| Animal Model: | Mice bearing LU2503 tumors patient derived xenograft (PDX) NSCLC model[1]. | | Dosage: | 15 mg/kg. | | Administration: | PO, BID (twice daily) for 13 days. | | Result: | Resulted in an 85% tumor regression and no body weight loss was observed after 21 days treatment. |
| Animal Model: | SCID/Beige mice bearing Ba/F3 ETV6-CSF1R tumors with average tumor size of ~180 mm3[1]. | | Dosage: | 5 and 15 mg/kg. | | Administration: | PO, BID (twice daily) for 10 days. | | Result: | Demonstrated the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively. |
| | References | [1] WO 2019023417 A1. |
| | CSF1R-IN-2 Preparation Products And Raw materials |
|